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RepublicBackground: V(D)J recombination takes place during
lymphocyte development to generate a large repertoire of
T- and B-cell receptors. Mutations in recombination-activating
gene 1 (RAG1) and RAG2 result in loss or reduction of V(D)
J recombination. It is known that different mutations in
RAG genes vary in residual recombinase activity and give rise
to a broad spectrum of clinical phenotypes.
Objective: We sought to study the immunologic mechanisms
causing the clinical spectrum of RAG deficiency.
Methods: We included 22 patients with similar RAG1 mutations
(c.519delT or c.368_369delAA) resulting in N-terminal
truncated RAG1 protein with residual recombination activity
but presenting with different clinical phenotypes. We studied
precursor B-cell development, immunoglobulin and T-cell
receptor repertoire formation, receptor editing, and B- and
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1124Results: Clinically, patients were divided into 3 main categories:
T2B2 severe combined immunodeficiency, Omenn syndrome,
and combined immunodeficiency. All patients showed a block in
the precursor B-cell development, low B- and T-cell numbers,
normal immunoglobulin gene use, limited B- and T-cell
repertoires, and slightly impaired receptor editing.
Conclusion: This study demonstrates that similar RAG
mutations can result in similar immunobiological effects but
different clinical phenotypes, indicating that the level of residual
recombinase activity is not the only determinant for clinical
outcome. We postulate a model in which the type and moment
of antigenic pressure affect the clinical phenotypes of these
patients. (J Allergy Clin Immunol 2014;133:1124-33.)
Key words: RAG deficiency, V(D)J recombination, B- and T-cell
receptor repertoire, receptor editing, autoimmunity, next generation
sequencing, immune repertoire analysis
Defects in V(D)J recombination result in a block in B- and
T-cell differentiation because formation of immunoglobulin and
T-cell receptors (TRs) is perturbed.1 This results in a combined
immunodeficiency (CID) of B and T cells. V(D)J recombination
is initiated by the recombination-activating gene (RAG) 1 and
RAG2 proteins by creating double-stranded breaks in the
immunoglobulin and TR loci. Subsequently, these breaks are
processed and repaired by proteins involved in nonhomologous
end joining. Thus far, genetic defects have been identified in the
RAG1, RAG2, Artemis, ligase IV (LIG4), XLF (Cernunnos), and
DNA-PKcs genes.2-8 The immunologic phenotypes and clinical
presentations of these mutations are different, depending on the
type of genetic defect (ie, null mutations or hypomorphic
mutations with residual V[D]J recombination activity). Espe-
cially for the RAG genes, many different mutations have been
described that give rise to residual activity of the mutated
RAG protein.9 Different RAG mutations can result in a broad
spectrum of clinical phenotypes, including severe combined
immunodeficiency (SCID), RAG deficiency (RAGD) with skin
inflammation and ab T-cell expansion (classical Omenn
syndrome [OS]), RAGD with skin inflammation but without
T-cell expansion (incomplete OS), RAGD with maternofetal
transfusion, RAGD with gd T-cell expansion, late-onset SCID,
RAGD with granulomas, and RAGD with CD4 cytopenia
and thymus hypoplasia.9,10 This broad spectrum of clinical
phenotypes impedes timely recognition of RAGD and might
thus delay treatment (hematopoietic stem cell transplantation).
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N-terminal truncating RAG1 mutations to study the effect of a
similar mutation on the clinical phenotype. These patients could
be divided into 3 main clinical phenotypes (ie, SCID, OS, and
CID, which includes the other phenotypes). We studied whether
key immunologic parameters (eg, precursor B-cell development,
B- and T-cell numbers, and B- and T-cell repertoire) might
explain the differences in clinical phenotypes.
METHODS
Cell samples and flow cytometric
immunophenotyping
Peripheral blood (PB), bone marrow (BM), and clinical data were obtained
according to the guidelines of the Medical Ethics Committee of the Erasmus
MC Rotterdam. Flow cytometric analysis was performed, as previously
described.8,11,12
RAG analysis and in vitro V(D)J recombination
assay
The RAG1 and RAG2 genes were amplified by means of PCR and
sequenced, as previously described.13 The level of recombination activity of
the RAG1 expression constructs was determined by using the recombination
plasmid pDVG93, as described previously.10,13 A TaqMan-based realtime
quantitative (RQ)-PCR was used to measure RAG1 and RAG2 transcription
levels in BM mononuclear cells, as described previously.14
T-cell receptor b analysis
T-cell receptor b (TRB) gene rearrangements were studied, as described
previously.15
Sequence analysis of Vk and Jk genes
Vk-Ck junctions were amplified in a multiplex PCR by using primers specific
for Vk1-5 families (VkI: 59-GTAGGAGACAGAGTCACCATCACT-39, VkII:
59-TGGAGAGCCGGCCTCCA-TCTC-39, VkIII: 59-GGGAAAGAGCCACC
CTCTCCTG-39, and VkIV: 59-GGCGAGAGGGCC-ACCATCAAC-39) and a
Ck primer (59-ACTTTGGCCTCTCTGGATA-39). PCR products were cloned in
the pGEM-Teasyvector (Promega,Madison,Wis) andprepared for sequencingon
the ABI Prism 3130 XL fluorescent sequencer (Applied Biosystems, Foster City,
Calif). Obtained sequences were analyzed with the IMGT database (http://imgt.
cines.fr/) to assign theVkand Jk genes.16,17 The productive and unique sequences
were used to determine the frequency of the Vk and Jk genes.
Repertoire analysis with next-generation
sequencing
The VH-JH junctions were amplified from post-Ficoll PBMCs in a
multiplex PCR by using the VH1-6 FR1 and JH consensus BIOMED-2primers.15 The primers were adapted for 454 sequencing by adding the
forward A or reverse B adaptor, the ‘‘TCAG’’ key, and the multiplex identifier
adaptor. PCR products were purified by using gel extraction (Qiagen,
Valencia, Calif) and Agencourt AMPure XP beads (Beckman Coulter,
Fullerton, Calif). Subsequently, the PCR concentration was measured with
the Quant-it Picogreen dsDNA assay (Invitrogen, Carlsbad, Calif). The
purified PCR products were sequenced on the 454 GS junior instrument
according to the manufacturer’s recommendations by using the GS junior
Titanium emPCR kit (Lib-A), sequencing kit, and PicoTiterPlate kit
(454 Life Sciences; Roche, Branford, Conn). By using the CLC genomic
workbench software, the samples were separated based on their multiplex
identifier sequence and trimmed, and reads with a quality score of less than
0.05 and less than 250 bp were discarded. The reads were uploaded to
IMGT HighV-Quest software.18 Subsequently, these output files were
uploaded to the custom Galaxy platform.19-21 Further processing was done
in the R programming language22 to generate the tabular and graphic outputs.
The complementary determining region 3 (CDR3) amino acid patterns were
visualized with WebLogo (http://weblogo.berkeley.edu/).23,24Statistics
Differences in absolute numbers of lymphocyte subsets were analyzed by
using the 2-tailed t test for independent samples (P < .05 was considered
significant) in GraphPad Prism software (GraphPad Software, La Jolla, Calif).RESULTS
Residual RAG1 activity in patients with N-terminal
truncating RAG1 mutations
Over the past 10 years, we identified one of the 2 mutations
resulting in N-terminal truncating RAG1mutations in 22 patients
(Tables I and II). These c.519delT (hereafter abbreviated as delT)
and c.368_369delAA (hereafter abbreviated as delAA) mutations
have been described before in several patients.13,25-29 They were
found to be hypomorphic13,27 because translation can be
reinitiated from the alternative start site methionine 202 (M202)
or M183, resulting in an N-terminal truncated RAG1 protein13
with the same (comparable) residual RAG1 activity (<5%
compared with wild type; Fig 1, A).13 Sixteen patients were
homozygous for the delAA or delT mutation, and 6 patients
were compound heterozygous (Table I). Three RAG1 mutations
found on the second allele were also analyzed in the in vitro
recombination assay, showing no residual RAG1 activity
(Fig 1, A). In addition, we determined the presence of poly-
morphisms in the RAG1 gene because these might influence the
recombination activity of RAG1. The only polymorphism found
was p.Arg249His, which was shown not to affect recombination
activity.2N-terminal truncating RAG1 mutations result in a
spectrum of clinical phenotypes
Although all patients had similar RAG1mutations, resulting in
the same N-terminal truncation of the RAG1 protein, the clinical
phenotypes varied substantially. The patients could be
divided into 3 main clinical phenotypes: ‘‘classical’’ T2B2
SCID (n 5 4), OS (n 5 9), and CID (n 5 9, Tables I and II).
The patients with ‘‘classical’’ SCID were defined as having low
B- and T-cell numbers and age at diagnosis before the first year
of life. The patients with OS all had generalized and pronounced
erythroderma. The patients with CID were given a diagnosis after
the first year of life and had greater than 14% gd T cells or normal
levels of T cells (P17 and P22). Despite the same N-terminal










erythroderma Hepatomegaly Splenomegaly Lymphadenopathy
SCID
P1 3
P2 6 6 BCG No ITP No No No
P3 8 8 Pneumonia and upper
airway infections
P4 6 8 BCG Mild
OS
P5 0 0.5 Erythroderma Yes Yes Yes
P6a 0 0.5 Recurrent pneumonia Erythroderma Yes No Yes
P7a 0 0.5 CMV No Erythroderma Yes Yes Yes
P8 0 3.5 CMV, Candida
species, MRSE
Severe pneumonia Erythroderma
P9 0 4 Erythroderma Yes No Yes
P10 1 1 Erythroderma Yes
P11 1.5 2 Erythroderma Yes
P12 1 8 BCG Recurrent pneumonia Erythroderma Yes Yes Yes









P14b 9 30 CMV, Candida species Recurrent
bronchopneumonia
Yes Yes No
P15b 9 18 CMV Recurrent
bronchopneumonia
Yes Yes No
P16c 1 11 CMV Chronic rhinitis No No No
P17 4 6 CMV, BCG Pneumonia Yes Yes Yes
P18 18 60 CMV, BCG, rhinovirus Yes AIHA, ITP No No No
P19 3 13 Candida species Chronic rhinitis and
bronchitis
AIHA No No No
P20 24 48 AIHA




AIHA No No No
P22c 0 17 Recurrent pneumonias,
bronchitis
No No No
Footnote symbols ‘‘a,’’ ‘‘b,’’ and ‘‘c’’ indicate relatives.
AIHA, Autoimmune hemolytic anemia; CMV, cytomegalovirus; ITP, idiopathic thrombocytopenic purpura; MRSE, methicillin-resistant staphylococcus epidermis.
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phenotypes strongly suggests that factors other than residual
RAG1 activity contribute to the clinical phenotype.All clinical phenotypes show a block in precursor
B-cell development
RAGD results in a block in the precursor B-cell differentiation
in BM at the B-cell stages during which V(D)J recombination of
the immunoglobulin genes takes place.11 The relative distribution
of pro-B, pre-BI, pre-BII, and immature B cells was assessed
in BM from 11 of 22 patients to investigate precursor B-cell
differentiation. In healthy children pro-B and pre-BI cells
constitute 20% to 25% of the precursor B cells (Fig 1, B). All
patients with ‘‘classical’’ SCID and OS, except P13, showed a
complete block before the pre–BII-cell stage (Fig 1, B), whereas
most of the patients with CID had a leaky block with greater than
10% pre-BII and immature B cells (Fig 1, B). RAG1 and RAG2
transcription levels were determined in the BMmononuclear cells
to exclude that differences in RAG1 transcription levels caused
these difference in precursor B-cell composition. It is known
that RAG1 and RAG2 transcription levels are correlated, andthat RAG1 and RAG2 levels in BM mononuclear cells depend
on the number of cells expressing RAG (pre-BI and pre-BII
cells).30 In all 11 studied patients, the RAG1 transcription level
was correlated to RAG2 (Fig 1, C), indicating that the differences
in severity of the precursor B-cell block were not caused by
differences in expression of RAG1. B-cell numbers in PB were
undetectable or very low in most patients, except P15, who had
normal levels (Table II). Correlating the percentage of pre-BII
and immature cells in BM with the number of peripheral B cells
showed that only patients with greater than 10% pre-BII and
immature B cells in BM (P13, P14, P15, P16, and P17) had
detectable B cells in PB. Collectively, these data indicate that
most patients with CID have a milder block in the precursor
B-cell composition and that only patients with a leaky block
have detectable B cells in the PB.Immunoglobulin heavy chain combinatorial
repertoire
In those patients with detectable peripheral B cells, we
studied the IGH V(D)J recombination repertoire. IGH gene
rearrangements were amplified from mononuclear cells derived





















P1 Homozygous 0.06 (1.4-8.0) 0.04 (0.9-5.5) 0.01 (0.4-2.3) 21.8 0.03 (0.6-3.1) 0.08 (0.1-1.4)
P2 Heterozygous p.P874GfsX82 0.1 (2.4-6.9) 0.06 (1.4-5.1) 0.01 (0.6-2.2) 32.1 24.4 0.01 (0.7-2.5) 0.4 (0.1-1.0)
P3 Homozygous 0.3 (1.6-6.7) 0.06 (1.0-4.6) 0.3 (0.4-2.1) 0 (0.6-2.7) 0.5 (0.2-1.2)
P4 Heterozygous p.R559S 0.3 (1.6-6.7) 0.2 (1.0-4.6) 0.04 (0.4-2.1) 7.7 10 0 (0.6-2.7) 0.1 (0.2-1.2)
OS
P5 Homozygous 20.1 (2.3-7.0) 7.56 (1.7-5.3) 12.75 (0.4-1.7) 4 0 (0.6-1.9) 2.59 (0.2-1.4)
P6a Homozygous 3.7 (2.3-6.5) 3.1 (1.5-5.0) 0.4 (0.5-1.6) 7.2 5.2 0.03 (0.6-3.0) 0.8 (0.1-1.3)
P7a Homozygous 36 (2.3-6.5) 10.7 (1.5-5.0) 24.9 (0.5-1.6) 3.1 1 0.03 (0.6-3.0) 0.4 (0.1-1.3)
P8 Homozygous 3.93 (2.3-6.5) 1.45 (1.5-5.0) 2.19 (0.5-1.6) 21.4 24.4 0.02 (0.6-3.0) 0.88 (0.1-1.3)
P9 Homozygous 1.84 (2.3-6.5) 1.48 (1.5-5.0) 0.3 (0.5-1.6) 4.6 3 0.004 (0.6-3.0) 1.64 (0.1-1.3)
P10 Heterozygous p.R737H 3.3 (2.3-7.0) 0.32 (1.7-5.3) 2.97 (0.4-1.7) 0.3 0.1 0 (0.6-1.9) 0.34 (0.2-1.4)
P11 Heterozygous p.R559S 4.33 (1.6-6.7) 4 (1.0-4.6) 0.27 (0.4-2.1) 0.01 (0.6-2.7) 0.93 (0.2-1.2)
P12 Homozygous 2.21 (2.3-6.5) 1.34 (1.5-5.0) 0.61 (0.5-1.6) 0.07 (0.6-3.0) 0.56 (0.1-1.3)
P13 Homozygous 0.6 (2.4-6.9) 0.6 (1.4-5.1) 0.01 (0.6-2.2) 4.8 2.9 0.07 (0.7-2.5) 0.2 (0.1-1.0)
CID
P14b Homozygous 0.3 (0.9-4.5) 0.1 (0.5-2.4) 0.07 (0.3-1.6) 35 49.5 0.4 (0.2-2.1) 0.8 (0.1-1.0)
P15b Homozygous 0.5 (1.4-8.0) 0.1 (0.9-5.5) 0.2 (0.4-2.3) 38.9 64.1 0.4 (0.6-3.1) 2.9 (0.1-1.4)
P16c Homozygous 0.16 (1.6-6.7) 0.07 (1.0-4.6) 0.02 (0.4-2.1) 26.9 46.3 0.09 (0.6-2.7) 0.32 (0.2-1.2)
P17 Homozygous 2.7 (1.6-6.7) 0.2 (1.0-4.6) 1.5 (0.4-2.1) 90.7 90.2 0.06 (0.6-2.7) 0.7 (0.2-1.2)
P18 Heterozygous p.R759C 0.53 (0.9-4.5) 0.07 (0.5-2.4) 0.12 (0.3-1.6) 57.2 0.12 (0.2-2.1) 1.32 (0.1-1.0)
P19 Homozygous 0.10 (1.6-6.7) 0.01 (1.0-4.6) 0.10 (0.4-2.1) 97.5 0.04 (0.6-2.7) 0.23 (0.2-1.2)
P20 Homozygous 0.77 (0.9-4.5) 0.25 (0.5-2.4) 0.24 (0.3-1.6) 41.7 0.02* (0.2-2.1) 0.18 (0.1-1.0)
P21 Heterozygous p.A444V 0.12 (0.9-4.5) 0.10 (0.5-2.4) 0.06 (0.3-1.6) 14.4 0.001 (0.2-2.1) 0.25 (0.1-1.0)
P22c Homozygous 1.97 (1.6-6.7) 0.42 (1.0-4.6) 1.50 (0.4-2.1) 42 0.29 (0.6-2.7) 0.72 (0.2-1.2)






FIG 1. RAG expression and precursor B-cell compartment.A, Recombination activity of the c.519delT (delT),
c.delA368/A369 (delAA), p.P874GX82, p.R559S, and p.R759C RAG1mutations was compared with wild-type
(WT) RAG1. Only the delT and the delAA RAG1 mutations result in low levels of residual recombination
activity. B, Composition of the precursor B-cell compartment in control subjects (n 5 9), 3 patients with
the ‘‘classical’’ SCID phenotype, 2 patients with OS, and 6 patients with CID. C, Relative RAG1 expression
levels correlated to RAG2 expression in all the analyzed RAG patients, as determined by using RQ-PCR.
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generation sequencing in healthy control subjects (PB and BM)
and 3 patients with CID (P15, P16, and P18). The frequency ofunique sequences in IGH genes was significantly lower in
patients with RAGD than in control subjects (Table III), which
is a reflection of the low numbers of B cells present in PB.





Control BM 35,472 18,241 (51.4) 8,633 (24.3) 26,839 (75.7)
P16 BM 12,195 3,325 (27.3) 1,629 (13.3) 10,566 (86.7)
Control PB 19,294 9,185 (61.2) 4,030 (20.9) 15,003 (77.8)
P15 PB 16,826 7,706 (45.8) 1,047 (6.2) 15,779 (93.8)
P16 PB 14,572 3,763 (25.8) 896 (6.1) 13,676 (93.9)
P18 PB 25,100 3,730 (14.9) 1,488 (5.9) 23,612 (94.1)
Numbers in parentheses indicate percentages. ‘‘Unproductive’’ refers to out-of-frame
rearrangements or rearrangements containing a stop codon in the CDR3 region.
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gene use was not restricted (Fig 2 and see Fig E1 in this article’s
Online Repository at www.jacionline.org). Forty-eight of the 57
IGHV genes used in control subjects were identified in the
patients with RAGD because were the 25 IGHD genes and all 6
IGHJ genes. IGHV, IGHD, and IGHJ gene uses were similar to
those seen in control subjects, although some genes were used
with different frequencies (Fig 2 and see Fig E1). Most strikingly,
JH6 use was lower whereas JH4 use was higher compared with
that seen in control subjects. The patients with RAGD had a
significantly lower frequency (5.9% to 6.2% vs 20.9% to 24.3%
in control subjects) of unproductive rearrangements (Table III),
as reported previously.31 Unproductive rearrangements were
defined as out-of-frame rearrangements or rearrangements with
a stop codon. Therefore even though the patients with RAGD
had reduced V(D)J recombination, leading to a limited TR and
immunoglobulin repertoire, the IGH gene use was similar to
that seen in control subjects without preferential use of the
proximal or distal genes.Selection of B cells is slightly impaired
OS is characterized by autoimmune-like clinical features,
including severe erythroderma, hepatosplenomegaly, and
lymphadenopathy.32,33 The immune dysregulation in patients
with OS might be caused by the severe abnormalities of thymic
architecture and impaired expression of autoimmune regulator
and tissue-specific antigens.34,35 In addition, hypomorphic Rag
mouse models have shown a disturbance in B-cell tolerance.36,37
In addition, patients with OS and also 1 patient with ‘‘classical’’
SCID and 4 patients with CID had autoimmunity, and all
displayed idiopathic thrombocytopenic purpura, autoimmune
hemolytic anemia, or both (Table I). Unfortunately, the thymic
architecture and autoimmune regulator and tissue-specific
antigen expression could not be studied in our patients, but we
were able to evaluate 3 parameters in the IGH sequences that
are associated with autoimmunity. These are characterized by
long CDR3s, and the frequency of IGHV4-34, which is known
to encode intrinsically self-reactive cold agglutinin antibodies
that recognize carbohydrate antigens on erythrocytes.38,39 The
distribution of the CDR3 length of the unique junctions in BM
and PB was similar to that seen in control subjects (Fig 3, A),
except patient 18, who seemed to have increased numbers of
junctions with a CDR3 of 16 and 22 amino acids. These junctions
with a CDR3 length of 22 amino acids displayed high similarity
(Fig 3, B). No sequence similarity was found when all
16-amino-acid CDR3s were compared (Fig 3, B), but 18.3% of
these junctions used IGHV6-1, and all these junctions had a highly
similar CDR3 sequence (Fig 3, B), which suggests that theymightrecognize a common antigenic determinant. The frequency of
long CDR3s (>_15 amino acids) was significantly lower in P15
and P16 (P < .0001) but not in P18 (Fig 3, C). The frequency of
IGHV4-34 use was significantly higher in P16 (P < .0001) and
P18 (P < .0001; Fig 3, D). From the 3 patients we analyzed,
P18 had autoimmunity, which was reflected by the high frequency
of IGHV4-34 use.
In addition to selection against long CDR3s, B-cell tolerance is
also generated by receptor editing of self-reactive B cells. These
self-reactive B cells are induced to express the RAG proteins and
edit their receptor light chains through available upstream Vkand
downstream Jk genes to change the affinity of their receptors.
Therefore the Vk-Jk junctions were amplified from 5 patients
with OS and 4 patients with CID. The IGKV gene use was
not significantly different from that seen in control subjects
(Fig 3, E), but less IGKJ5 genes were used in the patients with
RAGD (Fig 3, F). Therefore receptor editing seems partly
affected, as deduced from the very low IGKJ5 use.Difference between clinical phenotypes in absolute
numbers of T cells but not in T-cell repertoire
The hallmark of classical OS is an expansion of autologous
T cells with an HLA-DR1CD45RO1 phenotype and an oligoclo-
nal ab T-cell repertoire.40 Consistent with this, most of the
patients with OS had normal or increased CD31 T-cell numbers;
in addition, 2 patients with CID had normal numbers (P17 and
P22), whereas all other patients had low absolute numbers of
CD31 T cells (Table II). Remarkably, many patients had high
percentages (>14%) of gd T cells, including 2 patients with
‘‘classical’’ SCID, 1 patient with OS, and 8 patients with CID
(Table II). In addition, we determined the T-cell proliferation by
determining the dREC-cJa T-cell receptor excision circle
(TREC)41 content per 50 ng of DNA in 3 patients with ‘‘classical’’
SCID, 7 patients with OS, and 5 patients with CID. In 11 patients
TRECs were not detectable, and in the other 4 patients (P2, P5,
P7, and P18), the number of TRECs/50 ng of DNA was less
than 1 compared with 1346 75 TRECs/50 ng of DNA in control
subjects (n 5 7; age, 8 months to 11 years; data not shown),
meaning that the T cells that were present in these patients showed
extensive proliferation. Furthermore, the T-cell repertoire was
determined by testing the TRB gene rearrangements in 2 patients
with ‘‘classical’’ SCID, 3 patients with OS, and 2 patients with
CID. In all patients the TRB repertoire was clearly restricted
(Fig 4). Taken together, the T cells that were present in the
patients with RAGD showed extensive proliferation and had a
restricted TR repertoire.DISCUSSION
Many different RAG1 mutations have been reported to the
RAG mutation database.42 Although most are null mutations,
several have been described to result in residual recombinase
activity.11,13,25,27,43 Previously, it was hypothesized that null
mutations in RAG1 would result in ‘‘classical’’ T2B2 SCID and
that partial reduction of RAG activity would result in OS or an
intermediate late-onset SCID or OS phenotype.28 Over the last
few years, the spectrum of reported clinical phenotypes of
RAGDhas broadened and nowalso includesRAGDwithgdT-cell
expansion, RAGD with skin inflammation but without T-cell
expansion (incomplete OS), RAGD with granulomas, RAGD
A
B
FIG 2. Heat maps of the different combinations of immunoglobulin DH-JH (A) and VH-JH (B), as determined
in the unique junctions (defined by the unique combination of VH, DH, JH, and nucleotide sequences of
CDR3).
J ALLERGY CLIN IMMUNOL
VOLUME 133, NUMBER 4




FIG 3. Functional characteristics of IGH junctions. A, Functional characteristics of the IGH junctions were
determined in 3 patients with RAGD in PB or BM. Distribution of CDR3 length frequencies in BM and PB
was similar in control subjects and patients with RAGD; however, P18 had increased numbers of junctions,
with a CDR3 length of 16 and 23 amino acids. B, Sequence logo showed no similarity of the 16-amino-acid
CDR3s of P23 but high similarity of CDR3s of 16 amino acids using the IGHV6-1 gene and the 22-amino-acid
CDR3s. C, The frequency of long CDR3s (>_15 amino acids) was decreased in P15 and P16. D, IGHV4-34 use
was increased in P16 and P18. E and F, The percentage of IGKV and IGKJ genes was determined in 6 control
subjects, 5 patients with OS, and 4 patients with CID. IGKV use was normal (Fig 3, E), but hardly any IGKJ5
gene was used (Fig 3, F).
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and thymus hypoplasia.9,10 A few case reports have shown
that the same RAG mutation can result in a different clinical
phenotype.25,29,44,45 This study is the first to report an in-depth
immunobiological evaluation of 22 patients with RAGD with
similar RAG1 mutations, resulting in the same N-terminal
truncation of the RAG1 protein. These similar mutations result
in 3 different clinical phenotypes, which indicates that a specific
mutation does not predict a patient’s clinical phenotype.
Because all patients had similar mutations, the residual RAG1
protein activity was expected to be comparable among all
patients. The N-terminally truncated RAG1 protein is produced
through translation starting from an alternative start site (M183 or
M202), and hence the amount of protein is dependent on
how efficiently these start sites are used. Because the RAG1transcription level correlated with that of RAG2, we assume that
all patients had similar expression of the mutant RAG1 protein
(Fig 1,C). We cannot exclude that epigenetics and modifier genes
accounted for small differences in RAG1 protein expression.
Although a previous attempt to identify such modifier genes in
human subjects was not successful,46 studies in mouse models
could shed more light on the contribution of epigenetics and
modifier genes.
In our cohort V(D)J recombination was not completely
abolished but was strongly reduced because of the low residual
activity of the RAG1 protein. Reduced V(D)J recombination was
characterized by normal IGHV, IGHD, and IGHJ gene use,
without preferential use of proximal or distal genes. However,
as shown previously,31 the frequency of unproductive sequences
was significantly lower than in healthy control subjects,
FIG 4. TRB repertoire. TR spectratyping profiles of TRB gene rearrange-
ments using the BIOMED-2 TRB tube B. The upper 2 panels show the
monoclonal and the polyclonal controls. The patient panels SCID (P2
and P4), OS (P8), and CID (P21) show a restricted TRB repertoire.
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correct unproductive rearrangements by means of recombination
of the second IGH allele.
As a consequence of the reduced V(D)J recombination, fewer
B and T cells with a functional receptor can be produced. The
proliferation of the lymphocytes is increased to compensate for
low circulating B- and T-cell numbers. This idea is corroborated
by the low numbers of TRECs in patients with RAGD. The
increased proliferation of T cells might result in normal or
increased T-cell counts, especially in the patients with OS;
however, the corresponding TR repertoire in all the patients
with RAGD remains restricted.Most patients with RAGD showed clinical signs of
immune dysregulation, such as erythroderma, lymphadenopathy,
hepatosplenomegaly, idiopathic thrombocytopenic purpura, and
autoimmune hemolytic anemia. B cells have been shown to
contribute to the immune dysregulation seen in Rag mouse
models.36,37 Sera from these mice contained high-affinity
anti–double-stranded DNA and tissue-specific autoantibodies,
and B cells displayed impaired receptor editing. In addition, these
mice had increased serum B cell–activating factor levels, which
might rescue autoreactive B-cell clones. This increase in serum
B cell–activating factor levels was also seen in patients with
RAG-, Artemis-, and X-linked SCID.37 Similar to observations
in mice, most patients with RAGD did not use the IGKJ5 gene,
whereas IGKV gene use was normal. This suggests that receptor
editing in this group of patients with RAGD was slightly
impaired, which can either be a result of reduced recombination
activity caused by the RAG1 mutation or by low B-cell numbers
leading to reduced selection against autoreactive B cells.
The IGH repertoire was investigated for long CDR3s and
increased IGHV4-34 use, which are associated with autoreactive
antibodies.47,48 From the 3 patients with RAGD we analyzed,
only P18 had autoimmunity, which was reflected by an increased
VH4-34 gene use.
The patients divided into the 3 main clinical RAGD groups
hardly differed in their immunobiological parameters, and
consequently, we could not find any specific pattern that could
explain the different clinical phenotypes. On the basis of our
results and earlier reported data, we propose an explanatory
model for the development of different clinical phenotypes in
patients with RAGD with similar mutations (Fig 5). If RAGD
results in reduced V(D)J recombination, low B- and T-cell
numbers are produced with some (compensatory) clonal expan-
sion. This expansion might increase the B- and T-cell numbers
to even normal levels but does not change the limited repertoire.
In such limited repertoire the selection against autoreactive cells
is impaired. Provided the deficient immune system is not
activated, patients with RAGD are asymptomatic. However,
when the immune system will be activated by potentially a
wide range of different (auto)antigens, the type of antigen and
activated effector lymphocyte will have important consequences
for the clinical phenotype. In addition, the impaired negative
and positive selection of thymic lymphocytes and reduced
number of regulatory T cells might result in autoimmunity
when patients are exposed to autoantigens. This phenomenon
can occur at any early stage, even in utero, as shown by the fact
that patients with OS can have severe erythroderma already
at birth, which is unlikely to be triggered by infections. Addition-
ally, directly after birth, the skin and gastrointestinal tract become
colonized by commensal bacteria, which can trigger the chronic
diarrhea seen in most patients with RAGD. Key steps in the
development of a certain clinical phenotype will be the B- and
T-cell repertoire, the type of (auto)antigen exposure, the
specificity of the antigen receptors and timing, the cell type
involved in the immune activation, and the potential influence
of genetic variations in modifier genes. Variability in any of these
factors might eventually lead to different clinical phenotypes,
despite a similar genetic defect.
In conclusion, this study clearly shows that the type of RAG1
mutation and the level of residual RAG1 recombinase activity
are not the only determinants predicting the clinical phenotype,
as previously assumed. The clinical outcome of an individual
FIG 5. Model for development of clinical phenotype in patients with RAGD. RAGD results in reduced V(D)J
recombination, leading to fewer B and T cells with a limited repertoire. In an attempt to compensate for low
numbers, B and T cells start to proliferate, but the repertoire remains limited and imbalanced, so that
selection and immune regulation are impaired. Most likely the type of antigenic stimulation together with
the incomplete and imbalanced repertoire that has been developed will affect the eventual clinical
phenotype with immune dysregulation problems.
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(limited) immune receptor repertoire, (auto)antigen exposure, the
specificity of antigen receptors, and the timing and cell type
involved in immune activation. Therefore the clinical outcome
of patients with RAGD with similar mutations is extremely
difficult to predict.
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Clinical implications: RAGD can result in a broad spectrum of
clinical presentations, but the level of residual RAG activity is
not always predictive for the clinical outcome.REFERENCES
1. Schatz DG. V(D)J recombination. Immunol Rev 2004;200:5-11.
2. Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, et al.
RAG mutations in human B cell-negative SCID. Science 1996;274:97-9.
3. Moshous D, Callebaut I, de Chasseval R, Corneo B, Cavazzana-Calvo M, Le Deist F,
et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein,
is mutated in human severe combined immune deficiency. Cell 2001;105:177-86.
4. Ahnesorg P, Smith P, Jackson SP. XLF interacts with the XRCC4-DNA ligase IV
complex to promote DNA nonhomologous end-joining. Cell 2006;124:301-13.
5. Buck D, Malivert L, de Chasseval R, Barraud A, Fondaneche MC, Sanal O, et al.
Cernunnos, a novel nonhomologous end-joining factor, is mutated in human
immunodeficiency with microcephaly. Cell 2006;124:287-99.
6. O’Driscoll M, Gennery AR, Seidel J, Concannon P, Jeggo PA. An overview
of three new disorders associated with genetic instability: LIG4 syndrome,
RS-SCID and ATR-Seckel syndrome. DNA Repair (Amst) 2004;3:1227-35.7. van der Burg M, Ijspeert H, Verkaik NS, Turul T, Wiegant WW, Morotomi-Yano K,
et al. A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis
activation and nonhomologous end-joining. J Clin Invest 2009;119:91-8.
8. van der Burg M, van Veelen LR, Verkaik NS, Wiegant WW, Hartwig NG,
Barendregt BH, et al. A new type of radiosensitive T-B-NK1 severe combined
immunodeficiency caused by a LIG4 mutation. J Clin Invest 2006;116:137-45.
9. Niehues T, Perez-Becker R, Schuetz C. More than just SCID—the phenotypic
range of combined immunodeficiencies associated with mutations in the
recombinase activating genes (RAG) 1 and 2. Clin Immunol 2010;135:183-92.
10. Kuijpers TW, Ijspeert H, van Leeuwen EM, Jansen MH, Hazenberg MD,
Weijer KC, et al. Idiopathic CD41 T lymphopenia without autoimmunity or
granulomatous disease in the slipstream of RAG mutations. Blood 2011;117:
5892-6.
11. Noordzij JG, de Bruin-Versteeg S, Verkaik NS, Vossen JM, de Groot R, Bernatow-
ska E, et al. The immunophenotypic and immunogenotypic B-cell differentiation
arrest in bone marrow of RAG-deficient SCID patients corresponds to residual
recombination activities of mutated RAG proteins. Blood 2002;100:2145-52.
12. Noordzij JG, Verkaik NS, van der Burg M, van Veelen LR, de Bruin-Versteeg S,
Wiegant W, et al. Radiosensitive SCID patients with Artemis gene mutations
show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint
in bone marrow. Blood 2003;101:1446-52.
13. Noordzij JG, Verkaik NS, Hartwig NG, de Groot R, van Gent DC, van Dongen JJ.
N-terminal truncated human RAG1 proteins can direct T-cell receptor but not
immunoglobulin gene rearrangements. Blood 2000;96:203-9.
14. Boeckx N, Willemse MJ, Szczepanski T, van der Velden VH, Langerak AW,
Vandekerckhove P, et al. Fusion gene transcripts and Ig/TCR gene rearrange-
ments are complementary but infrequent targets for PCR-based detection of
minimal residual disease in acute myeloid leukemia. Leukemia 2002;16:368-75.
15. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender
FL, et al. Design and standardization of PCR primers and protocols for detection of
clonal immunoglobulin and T-cell receptor gene recombinations in suspect
lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-
3936. Leukemia 2003;17:2257-317.
16. Lefranc MP. IMGT databases, web resources and tools for immunoglobulin and
T cell receptor sequence analysis, http://imgt.cines.fr. Leukemia 2003;17:260-6.
J ALLERGY CLIN IMMUNOL
VOLUME 133, NUMBER 4
IJSPEERT ET AL 113317. Lefranc MP. IMGT, the international ImMunoGeneTics database. Nucleic Acids
Res 2003;31:307-10.
18. Alamyar E, Duroux P, Lefranc MP, Giudicelli V. IMGT tools for the nucleotide
analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires,
polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST
for NGS. Methods Mol Biol 2012;882:569-604.
19. Goecks J, Nekrutenko A, Taylor J, Galaxy T. Galaxy: a comprehensive approach
for supporting accessible, reproducible, and transparent computational research
in the life sciences. Genome Biol 2010;11:R86.
20. Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M, et al.
Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol
Biol 2010;Chapter 19:Unit 19.10.1-21.
21. Giardine B, Riemer C, Hardison RC, Burhans R, Elnitski L, Shah P, et al. Galaxy:
a platform for interactive large-scale genome analysis. GenomeRes 2005;15:1451-5.
22. R: a language and environment for statistical computing. Vienna: R Foundation for
Statistical Computing; 2013.
23. Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo
generator. Genome Res 2004;14:1188-90.
24. Schneider TD, Stephens RM. Sequence logos: a new way to display consensus
sequences. Nucleic Acids Res 1990;18:6097-100.
25. Corneo B, Moshous D, Gungor T, Wulffraat N, Philippet P, Le Deist FL, et al.
Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J
recombinase activity can cause either T-B-severe combined immune deficiency
or Omenn syndrome. Blood 2001;97:2772-6.
26. de Villartay JP, Lim A, Al-Mousa H, Dupont S, Dechanet-Merville J, Coumau-
Gatbois E, et al. A novel immunodeficiency associated with hypomorphic
RAG1 mutations and CMV infection. J Clin Invest 2005;115:3291-9.
27. Santagata S, Gomez CA, Sobacchi C, Bozzi F, Abinun M, Pasic S, et al. N-terminal
RAG1 frameshift mutations in Omenn’s syndrome: internal methionine usage leads
to partial V(D)J recombination activity and reveals a fundamental role in vivo for
the N-terminal domains. Proc Natl Acad Sci U S A 2000;97:14572-7.
28. Villa A, Sobacchi C, Notarangelo LD, Bozzi F, Abinun M, Abrahamsen TG, et al.
V(D)J recombination defects in lymphocytes due to RAG mutations: severe
immunodeficiency with a spectrum of clinical presentations. Blood 2001;97:81-8.
29. Martinez-Martinez L, Vazquez-Ortiz M, Gonzalez-Santesteban C, Martin-Nalda A,
Vicente A, Plaza AM, et al. From severe combined immunodeficiency to Omenn
syndrome after hematopoietic stem cell transplantation in a RAG1 deficient family.
Pediatr Allergy Immunol 2012;23:660-6.
30. van Zelm MC, van der Burg M, de Ridder D, Barendregt BH, de Haas EF, Reinders
MJ, et al. Ig gene rearrangement steps are initiated in early human precursor B cell
subsets and correlate with specific transcription factor expression. J Immunol 2005;
175:5912-22.
31. Ohm-Laursen L, Nielsen C, Fisker N, Lillevang ST, Barington T. Lack of
nonfunctional B-cell receptor rearrangements in a patient with normal B cell
numbers despite partial RAG1 deficiency and atypical SCID/Omenn syndrome.
J Clin Immunol 2008;28:588-92.
32. Ochs HD, Davis SD, Mickelson E, Lerner KG, Wedgwood RJ. Combined
immunodeficiency and reticuloendotheliosis with eosinophilia. J Pediatr 1974;85:
463-5.33. Omenn GS. Familial Reticuloendotheliosis with Eosinophilia. N Engl J Med 1965;
273:427-32.
34. Cavadini P, Vermi W, Facchetti F, Fontana S, Nagafuchi S, Mazzolari E, et al.
AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest
2005;115:728-32.
35. Poliani PL, Facchetti F, Ravanini M, Gennery AR, Villa A, Roifman CM, et al.
Early defects in human T-cell development severely affect distribution and
maturation of thymic stromal cells: possible implications for the pathophysiology
of Omenn syndrome. Blood 2009;114:105-8.
36. Cassani B, Poliani PL, Marrella V, Schena F, Sauer AV, Ravanini M, et al.
Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the
Rag2 mouse model of Omenn syndrome. J Exp Med 2010;207:1525-40.
37. Walter JE, Rucci F, Patrizi L, Recher M, Regenass S, Paganini T, et al. Expansion
of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent
immunodeficiency. J Exp Med 2010;207:1541-54.
38. Pascual V, Victor K, Lelsz D, Spellerberg MB, Hamblin TJ, Thompson KM, et al.
Nucleotide sequence analysis of the V regions of two IgM cold agglutinins.
Evidence that the VH4-21 gene segment is responsible for the major cross-
reactive idiotype. J Immunol 1991;146:4385-91.
39. Silberstein LE, Jefferies LC, Goldman J, Friedman D, Moore JS, Nowell PC, et al.
Variable region gene analysis of pathologic human autoantibodies to the related i
and I red blood cell antigens. Blood 1991;78:2372-86.
40. de Saint-Basile G, Le Deist F, de Villartay JP, Cerf-Bensussan N, Journet O,
Brousse N, et al. Restricted heterogeneity of T lymphocytes in combined
immunodeficiency with hypereosinophilia (Omenn’s syndrome). J Clin Invest
1991;87:1352-9.
41. Breit TM, Verschuren MC, Wolvers-Tettero IL, Van Gastel-Mol EJ, Hahlen K, van
Dongen JJ. Human T cell leukemias with continuous V(D)J recombinase activity
for TCR-delta gene deletion. J Immunol 1997;159:4341-9.
42. RAG1 mutation database. Available at: http://www.uta.fi/imt/bioinfo/RAG1base.
Accessed December 27, 2013.
43. Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, et al. Partial V(D)
J recombination activity leads to Omenn syndrome. Cell 1998;93:885-96.
44. Chou J, Hanna-Wakim R, Tirosh I, Kane J, Fraulino D, Lee YN, et al. A novel
homozygous mutation in recombination activating gene 2 in 2 relatives with
different clinical phenotypes: Omenn syndrome and hyper-IgM syndrome.
J Allergy Clin Immunol 2012;130:1414-6.
45. Pasic S, Djuricic S, Ristic G, Slavkovic B. Recombinase-activating gene 1
immunodeficiency: different immunological phenotypes in three siblings.
Acta Paediatr 2009;98:1062-4.
46. Haq IJ, Steinberg LJ, Hoenig M, van der Burg M, Villa A, Cant AJ, et al.
GvHD-associated cytokine polymorphisms do not associate with Omenn syndrome
rather than T-B- SCID in patients with defects in RAG genes. Clin Immunol 2007;
124:165-9.
47. Klonowski KD, Primiano LL, Monestier M. Atypical VH-D-JH rearrangements in
newborn autoimmune MRL mice. J Immunol 1999;162:1566-72.
48. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC.



















































































































































































































































































































































































































































































FIG E1. Immunoglobulin heavy chain gene usage. Frequency of IGHV (A), IGHD (B), and IGHJ (C) gene use
in control BM and PB and in P16 BM and PB, P15 PB, and P18 PB.
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